The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma

作者全名："Gong, Sainan; Quan, Quan; Meng, Yu; Wu, Jingxian; Yang, Shuang; Hu, Jiaming; Mu, Xiaoling"

作者地址："[Gong, Sainan; Yang, Shuang; Hu, Jiaming; Mu, Xiaoling] Chongqing Med Univ, Affiliated Hosp 1, Dept Gynecol, Chongqing 400016, Peoples R China; [Quan, Quan] First Peoples Hosp, Chongqing Liangjiang New Area, Dept Gynecol, Chongqing 401121, Peoples R China; [Meng, Yu] Chongqing Med Univ, Univ Town Hosp Affiliated, Dept Phys Examinat Ctr, Chongqing 400042, Peoples R China; [Wu, Jingxian] Chongqing Med Univ, Affiliated Hosp 1, Dept Pathol, Chongqing 400016, Peoples R China"

通信作者："Mu, XL (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Gynecol, Chongqing 400016, Peoples R China."

来源：HELIYON

ESI学科分类：　

WOS号：WOS:001042797600001

JCR分区：Q1

影响因子：3.4

年份：2023

卷号：9

期号：7

开始页：　

结束页：　

文献类型：Article

关键词：CA125; HE4; Endometrial endometrioid carcinoma; Prediction; Monitoring; Risk stratification

摘要："To evaluate the role of serum human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) levels for predicting and monitoring the recurrence of endometrial endometrioid carcinoma (EEC) and assessing preoperative risk stratification in EEC patients. A total of 434 EEC patients were selected for this retrospective study between May 2011 and August 2018. Serum HE4 and CA125 levels were analyzed before the initial treatment, at the first postoperative follow-up, and at recurrence or the last follow-up. Patients were risk stratified according to the European Society for Medical Oncology (ESMO), European Society for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) guideline. We compared the ability of these biomarkers for prediction and monitoring by performing receiver operating characteristic curve analysis and identified optimal cut-off values by determining the Youden index. Kaplan-Meier analyses were also performed to determine prognostic value. Preoperative serum HE4 was identified as a significant predictor for the recurrence of EEC (p = 0.014). Preoperative serum HE4 and CA125 levels were related to depth of myometrial invasion, lymph node status and FIGO stage. Serum HE4 and CA125 levels were both statistically significant markers for monitoring the recurrence of EEC (P = 0.000 for each biomarker). When combined, the two markers showed higher levels of sensitivity and specificity. The two biomarkers were also significant biomarkers for evaluating the risk stratification of patients undergoing lymphadenectomy (P = 0.000 for each biomarker). For premenopausal stage I patients, preoperative serum HE4 and CA125 levels were significant predictors of the need for ovarian preservation (P = 0.000 and P = 0.002, respectively). For premenopausal patients with stage I intramucosal differentiation, preoperative serum levels of HE4 were significant predictors for fertility preservation (P = 0.024). Preoperative serum HE4 level can be used to predict the recurrence of EEC. Postoperative serum HE4 and CA125 levels can be used to monitor the recurrence of EEC and are more sensitive when combined. Preoperative serum levels of CA125 and HE4 levels are of significant value for risk stratification in EEC patients."

基金机构：　

基金资助正文：